Patients with light chain amyloidosis (AL) often have delayed diagnosis and present with significant symptomatology; this may result in decreased quality of life (QOL). We prospectively employ a has predictive value. Baseline patient reported fatigue is an independent prognostic factor for survival. Survival at one year was associated with significant improvement in QOL.
| I N T R O D U C T I O N
Is it possible to routinely and efficiently incorporate input from the patient perspective amid the time-and resource-restricted modern hematology practice? Clinicians depend on various factors (laboratories, imaging, and pathology) to develop care plans; however patient selfreport may provide some of the best information. A patient reported outcome (PRO) is defined as all perceived changes in health related aspects such as symptoms, functionality, and quality of life (QOL) reported by the patient without introduction of bias by any third party. 1 Symptom monitoring of cancer patients can direct subsequent treatment strategies; and inform about toxicity from treatment or illness.
The current standard approach for symptom and QOL assessment is to inquire during visits as time permits. If clinicians do not ask, it is up to the patient to bring up an issue. Unfortunately, this method is often inadequate because frequently no issues are mentioned. 2 Even if issues are raised, multiple studies demonstrate providers underestimate those symptoms and/or the impact on wellbeing and QOL. [3] [4] [5] Collection of PRO data has the potential to enhance communication and care management by helping providers understand the effect of treatments and disease on patients' lives and wellbeing.
Light chain amyloidosis (AL) is a disease with multi-organ damage and a wide spectrum of presentations. Patients with AL often have delayed diagnosis and present with significant symptomatology, which may result in lower overall QOL. 10, 11 These issues can results in increased depression and anxiety in AL, one study showed rates of of anxiety and depression in AL of 37% and 46.7%, respectively,much higher than the general population. 12 Moreover, the treatments employed for AL include multidrug chemotherapy and/or high dose chemotherapy followed by autologous stem cell transplant (ASCT) with significant potential toxicities. 13, 14 With increasing numbers of new therapies for AL and improving survival, it is important to understand the impact on QOL.
At Mayo Clinic, we prospectively employ a "Hematology Patient
Reported Symptom Screen" (HPRSS) which is a three point questionnaire on fatigue, pain and overall QOL. The aim of this study is to gain a better understanding of baseline QOL in newly diagnosed AL and determine if the HPRSS parameters predict for various clinical outcomes.
| M E T H O D S

| Patients
We retrospectively reviewed all AL patients seen at Mayo Clinic Roch- 
| QOL assessment
The HPRSS questions are, "Over the past week, how would you describe your level of fatigue, pain, and overall QOL on average? Please rate your symptoms on a scale from 0 to 10 with 10 being the worst for fatigue or pain, and 10 being the best for overall QOL." The Linear
Analog Self-Assessment (LASA) is a single item PRO that is a reliable and validated measure of multiple domains of QOL (fatigue, pain, and QOL). [15] [16] [17] Patients completed the LASA items on paper while waiting to see their provider. A clinical assistant entered the information into the electronic medical record, and both the paper form and electronic entry were available for review by clinicians at the time of visit. Scores were abstracted from visits at time of diagnosis, and at twelve months plus or minus 1 month post-diagnosis. Scores greater than or equal to five were considered clinically deficient for fatigue and pain, and those less than or equal to five deficient for QOL. 18 Although a minimally clinical significant difference is one half a standard deviation up or down from baseline (increase/decrease 1 point); to be conservative, we considered a 2-point difference in serial scores a clinically meaningful "change" over time. [19] [20] [21] HPRSS scores were compared with published normative data from various populations (advanced cancer, hematologic cancers, and hospice) that also used single item LASA scales. 20 
| Statistical analysis
The Fisher's exact test was used to determine the differences between nominal groups. A two-sided P-value < 0.05 was considered statistically significant. For purposes of multiple comparisons, a Bonferroni adjustment was applied to the P values. Overall survival (OS) was calculated Table 1 based on one year survival and completion of HPRSS at one year.
There were significant differences in baseline HPRSS between those that lived greater than one year and the early death patients in 
| AL patients QOL compared with other normative populations
Fifty-one percent of our AL patients had clinically meaningful deficits in baseline QOL (LASA 5). We compared these data to previously published normative LASA data. 20 Clinical deficits in QOL are found in 21% of advanced cancer patients, 13% of hematologic malignancy patients, and 42% of hospice patients. Using the same normative data set, mean normative QOL (standard deviations) LASA scores for advanced cancer, hematologic malignancy, and hospice patients are 7.26 (2.31), 7.33 (2.03), and 5.89 (2.03), respectively; in contrast our AL patients had a QOL of 5.57 (2.50). Using a two-sample t-test, there was a significant difference between our AL patients and advanced cancer patients (P < 0.0001) and other hematologic cancer patients (P 5 0.0001), but no difference in LASA QOL scores between our AL group and published hospice patients (P 5 0.3789).
| QOL assessments at one year
When analyses were restricted to the 125 patients with HPRSS measurements at 12 months, we found that over time QOL scores improved (Table 2 ). When we included the 102 patients who had early deaths (< 12 months) to the comparison, the early death patients had the worst baseline parameters. There were significant differences across all four groups for most characteristics (Table 2) . at one year had an inferior OS, but these patients were less likely to have ASCT, hematologic response, and a normal NT pro-BNP (P < 0.0001).
| Survival and prognosis
| DISCUSSION
AL amyloidosis is an insidious disease whereby amyloid fibrils deposit and cause nonspecific signs and symptoms that result in delay in diagnosis, multiorgan failure, and death. 22 There is limited PRO data in these patients. 23 Using simple LASA indices, we made three important observations. First, we demonstrate that newly diagnosed AL amyloidosis patients have similar average baseline QOL than a normative data set of hospice patients and significantly worse than patients with advanced cancers or hematologic cancers. 20 Second, LASA indices of QOL 5 and of fatigue 5 were strong predictors of death, and baseline fatigue was an independent prognostic factor. Third, even patients with very poor baseline QOL and/or fatigue can improve, though they had a very high-risk of death.
High risk AL amyloidosis patients based on staging had worse baseline QOL and more significant fatigue. 24, 25 In this study, we demonstrate that patients who died early (<12 months) were in the highest risk categories by AL amyloid staging systems, which translated to the worst baseline QOL and fatigue scores. In addition, the baseline QOL of patients who were not eligible for stem cell transplant was significantly worse that those who were eligible. This suggests that the LASA scores correlated well with disease burden at diagnosis. Seldin et al.
also demonstrated the correlation of QOL and clinical features of AL amyloidosis using the Short Form General Health Survey (SF-36).
26
The SF-36 is a widely used, valid and reliable PRO QOL assessment for multiple chronic diseases, and unlike LASA is a detailed multi-item questionnaire. Pain scores were consistently low, did not worsen over time, and do not appear to be relevant for this disease process in both our study and the Seldin study. 26 The findings of this study support the prognostic value of healthrelated QOL, which has been shown to predict for survival in multiple prior studies. 15, 27, 28 AL amyloidosis patients with clinically deficient baseline scores in QOL and fatigue have more advanced disease, have a higher mortality rate, and lower rates of hematologic response. Moreover, baseline patient-reported fatigue in this study was an independent prognostic factor for survival even when ASCT and Mayo stage were included in the analysis. In contrast, physician-reported PS was not prognostic, consistent with literature that demonstrates that patient reported assessments of functional wellbeing and QOL are more reliable than clinician accounts. 2, 29, 30 This is important to highlight since physician-reported PS dictates treatment options and clinical trial eligibility. It would be best to also incorporate patient reports for consideration of clinical trial eligibility, patient stratification, assess prognosis, and determine functional wellbeing. This is particularly true for rare diseases like AL amyloidosis that often have wide-spread effects not easily measured or imaged.
Limiting the analysis to patients surviving for one year highlighted the fact that the sickest patients (worst baseline QOL, highest troponin T, NT pro-BNP, and DFLC) had one of two courses-death or clinical improvement. In contrast, the healthiest patients with the best baseline QOL worsened by at least 2 points on the LASA scale at 1 year, presumably from the effects of chemotherapy, in particular ASCT.
The limitations of this study include the small sample size and retrospective nature. Most patients seen are referred and thus have the capability to travel and evaluated at an academic center, so these results may not be generalizable to all AL patients. There were 75 patients alive at 12 months with missing HPRSS scores, which could also be a confounder. Larger prospective studies would be needed to confirm these results and understand long-term changes in QOL for AL amyloidosis.
In conclusion, this study demonstrates the predictive power of PRO collection with respect to QOL and fatigue in newly diagnosed AL amyloidosis patients. Patient-reported fatigue at diagnosis is an independent prognostic factor for survival. Collection of PROs is especially important for patients with chronic conditions, complex treatments that have a significant impact on daily life like AL amyloidosis. The HPRSS is a simple way to incorporate the patient's perspective into clinical practice, and compliment the regular day-to-day clinical assessment.
